| Dr Thomas Christian Weart, MD | |
|
1401 Johnston Willis Dr Ste 100, North Chesterfield, VA 23235-4730 | |
| (804) 330-7990 | |
| (804) 330-2701 |
| Full Name | Dr Thomas Christian Weart |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 12 Years |
| Location | 1401 Johnston Willis Dr Ste 100, North Chesterfield, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518226034 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 0101264391 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cjw Medical Center | Richmond, VA | Hospital |
| Henrico Doctors' Hospital | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ivyrehab Sept, Llc | 7911990908 | 1137 |
| Virginia Cancer Institute Incorporated | 8628048378 | 41 |
News Archive
Today three leading national public health organizations – the National Coalition of STD Directors (NCSD), the American Social Health Association (ASHA), and the National Family Planning & Reproductive Health Association (NFPRHA) – renewed their call for sexual health policy to be driven by science instead of politics.
Earlier results from the same researcher had suggested a survival benefit of group therapy for women with metastatic breast cancer. However, the new study did find that women with estrogen receptor (ER) negative tumors did show survival benefit, and that group therapy improved quality of life (QOL).
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).
A federal district judge in Oregon blocked new rules for the federal family planning program issued by the Trump administration and due to take effect May 3. It's one of several cases out to thwart the changes that would effectively evict Planned Parenthood from the Title X program.
› Verified 8 days ago
| Entity Name | Virginia Cancer Institute Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730130980 PECOS PAC ID: 8628048378 Enrollment ID: O20040729000501 |
News Archive
Today three leading national public health organizations – the National Coalition of STD Directors (NCSD), the American Social Health Association (ASHA), and the National Family Planning & Reproductive Health Association (NFPRHA) – renewed their call for sexual health policy to be driven by science instead of politics.
Earlier results from the same researcher had suggested a survival benefit of group therapy for women with metastatic breast cancer. However, the new study did find that women with estrogen receptor (ER) negative tumors did show survival benefit, and that group therapy improved quality of life (QOL).
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).
A federal district judge in Oregon blocked new rules for the federal family planning program issued by the Trump administration and due to take effect May 3. It's one of several cases out to thwart the changes that would effectively evict Planned Parenthood from the Title X program.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Christian Weart, MD 7202 Glen Forest Dr Ste 200, Richmond, VA 23226-3780 Ph: (804) 200-6240 | Dr Thomas Christian Weart, MD 1401 Johnston Willis Dr Ste 100, North Chesterfield, VA 23235-4730 Ph: (804) 330-7990 |
News Archive
Today three leading national public health organizations – the National Coalition of STD Directors (NCSD), the American Social Health Association (ASHA), and the National Family Planning & Reproductive Health Association (NFPRHA) – renewed their call for sexual health policy to be driven by science instead of politics.
Earlier results from the same researcher had suggested a survival benefit of group therapy for women with metastatic breast cancer. However, the new study did find that women with estrogen receptor (ER) negative tumors did show survival benefit, and that group therapy improved quality of life (QOL).
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).
A federal district judge in Oregon blocked new rules for the federal family planning program issued by the Trump administration and due to take effect May 3. It's one of several cases out to thwart the changes that would effectively evict Planned Parenthood from the Title X program.
› Verified 8 days ago
James T May Iii, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1401 Johnston Willis Dr Ste 100, North Chesterfield, VA 23235 Phone: 804-330-7990 Fax: 804-330-2701 | |
Dr. Brian Thomas Bradshaw, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2500 Pocoshock Pl, Suite 103, North Chesterfield, VA 23235 Phone: 804-745-2200 Fax: 804-745-9224 | |
Dr. Guita Ghadiri, M.D. Hematology & Oncology Medicare: May Accept Medicare Assignments Practice Location: 1901 Huguenot Rd, Suite 309, North Chesterfield, VA 23235 Phone: 804-955-4864 | |
Mohit Jindal, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 169 Wadsworth Dr, North Chesterfield, VA 23236 Phone: 804-330-4021 Fax: 804-272-6895 | |
Muhammad Nauman Athar, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1000 Boulders Pkwy, Suite 102, North Chesterfield, VA 23225 Phone: 804-320-4243 Fax: 804-622-0552 | |
Dr. Suhein D Galloza Rivera, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1457 Johnston Willis Dr, North Chesterfield, VA 23235 Phone: 804-716-5520 Fax: 804-716-6687 | |
Gabriel David Mccoy, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1401 Johnston Willis Dr Ste 100, North Chesterfield, VA 23235 Phone: 804-330-7990 Fax: 804-330-2701 |